1. Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model
- Author
-
Miyake, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Miyake, Masuyo, Igarashi, Kentaro, Zhang, Zhiying, Murakami, Takashi, Li, Yunfeng, Nelson, Scott D., Elliott, Irmina, Russell, Tara, Singh, Arun, Hiroshima, Yukihiko, Momiyama, Masashi, Matsuyama, Ryusei, Chishima, Takashi, Endo, Itaru, Eilber, Fritz C., and Hoffman, Robert M.
- Abstract
ABSTRACTGastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit is a rare type of sarcoma. The aim of this study was to determine drug sensitivity for a regionally-recurrent case of GIST using a patient-derived orthotopic xenograft (PDOX) model. The PDOX model was established in the anterior wall of the stomach. GIST PDOX models were randomized into 5 groups of 6 mice each when the tumor volume reached 60 mm3: G1, control group; G2, imatinib group (oral administration (p.o.), daily, for 3 weeks); G3, sunitinib group (p.o., daily, for 3 weeks); G4, regorafenib (p.o., daily, for 3 weeks); G5, pazopanib (p.o., daily, for 3 weeks). All mice were sacrificed on day 22. Tumor volume was evaluated on day 0 and day 22 by laparotomy. Body weight were measured 2 times per week. Though regorafenib is third-line therapy for GIST, it was the most effective drug and regressed the tumor significantly (p < 0.001). Sunitinib suppressed tumor growth compared to the control group (p = 0.002). Imatinib, first-line therapy for GIST, and pazopanib did not have significant efficacy compared to the control group (p = 0.886, p = 0.766). The implications of this result is discussed for GIST patients.
- Published
- 2018
- Full Text
- View/download PDF